Tonix Pharmaceuticals Announces Preliminary Third Quarter 2026 Financial Results
8-K
Tonix Pharmaceuticals Receives Paragraph IV Notice from Dr. Reddy's for Generic TONMYA
8-K
Tonix Pharmaceuticals Announces Coverage Agreement for TONMYA® with Pharmacy Benefit Manager for Medicare Part D Beneficiaries
8-K
Tonix Pharmaceuticals Appoints Thomas Englese as Chief Commercial Officer
8-K
Tonix Pharmaceuticals Appoints CEO Dr. Seth Lederman as Interim Chief Medical Officer
Prospectus
TYPE
HEADLINE
FILED AT
424B5
REGISTERED OFFERING
424B5
November 2025 ATM | Offering amount: $400,000,000 | Amount sold to date: $103,100,000
424B5
Lincoln Park SPA - The price at which shares are sold to Lincoln Park on a given day is determined by the market price of the company's common stock, as specified in the Purchase Agreement. For Regular Purchases, the price per share is the lesser of the lowest sale price on the purchase date or the average of the three lowest closing sale prices over the ten days prior. For Accelerated Purchases, the price is 97% of the lesser of the volume-weighted average price during the measurement period or the closing sale price on the purchase date. The amount of shares sold is determined by the company's discretion, subject to certain conditions. On any business day, the company can direct Lincoln Park to purchase up to $500,000 worth of stock, which can increase to $750,000 or $1,000,000 if the stock price is above certain thresholds. Additionally, the company can direct Lincoln Park to make Accelerated Purchases, which are limited to 300% of the Regular Purchase amount or 30% of the trading volume on the Nasdaq on the following day.
424B5
June 2025 ATM
424B5
Form 424B5 - Prospectus [Rule 424(b)(5)]
424B5
ATM | Offering amount: $150,000,000 | Amount sold to date: $34,900,000
